Nuvation Bio Inc. (NUVB) stock
NUVBNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 4/30107% above fair value
$3.78−0.12 (-3.08%)
Close on Nov 18, 2026Market cap $1.33BP/E –Yield –
Nuvation Bio revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Nuvation Bio's revenue for the twelve months ending Jun 30, 2026 was $169.90M, up 1083.6% year over year. For fiscal 2025 it was $62.90M, up 699.0% from the year before.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $62.90M | +699.0% |
| FY2024 | Dec 31, 2024 | $7.87M | – |
| FY2023 | Dec 31, 2023 | $0 | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $31.69M | +555.6% |
| Q1 FY2026 | Mar 31, 2026 | $83.23M | +2598.7% |
| Q4 FY2025 | Dec 31, 2025 | $41.87M | +633.1% |
| Q3 FY2025 | Sep 30, 2025 | $13.12M | +1704.7% |
| Q2 FY2025 | Jun 30, 2025 | $4.83M | +236.8% |
| Q1 FY2025 | Mar 31, 2025 | $3.08M | – |
| Q4 FY2024 | Dec 31, 2024 | $5.71M | – |
| Q3 FY2024 | Sep 30, 2024 | $727.00K | – |
| Q2 FY2024 | Jun 30, 2024 | $1.44M | – |
| Q1 FY2024 | Mar 31, 2024 | $0 | – |
| Q4 FY2023 | Dec 31, 2023 | $0 | – |
| Q3 FY2023 | Sep 30, 2023 | $0 | – |
| Q2 FY2023 | Jun 30, 2023 | $0 | – |
See a number that looks wrong?